146 related articles for article (PubMed ID: 15635635)
1. The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 (BRS3).
Boyle RG; Humphries J; Mitchell T; Showell GA; Apaya R; Iijima H; Shimada H; Arai T; Ueno H; Usui Y; Sakaki T; Wada E; Wada K
J Pept Sci; 2005 Mar; 11(3):136-41. PubMed ID: 15635635
[TBL] [Abstract][Full Text] [Related]
2. Systematic optimization of a lead-structure identities for a selective short peptide agonist for the human orphan receptor BRS-3.
Weber D; Berger C; Heinrich T; Eickelmann P; Antel J; Kessler H
J Pept Sci; 2002 Aug; 8(8):461-75. PubMed ID: 12212809
[TBL] [Abstract][Full Text] [Related]
3. Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3.
Mantey SA; Coy DH; Entsuah LK; Jensen RT
J Pharmacol Exp Ther; 2004 Sep; 310(3):1161-70. PubMed ID: 15102928
[TBL] [Abstract][Full Text] [Related]
4. Discovery of high affinity bombesin receptor subtype 3 agonists.
Wu JM; Nitecki DE; Biancalana S; Feldman RI
Mol Pharmacol; 1996 Nov; 50(5):1355-63. PubMed ID: 8913368
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for agonism in the BB3 receptor: an epitope located on the interface of transmembrane-III, -VI, and -VII.
Gbahou F; Holst B; Schwartz TW
J Pharmacol Exp Ther; 2010 Apr; 333(1):51-9. PubMed ID: 20065020
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2).
Darker JG; Brough SJ; Heath J; Smart D
J Pept Sci; 2001 Nov; 7(11):598-605. PubMed ID: 11763364
[TBL] [Abstract][Full Text] [Related]
7. Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3.
Ryan RR; Weber HC; Hou W; Sainz E; Mantey SA; Battey JF; Coy DH; Jensen RT
J Biol Chem; 1998 May; 273(22):13613-24. PubMed ID: 9593699
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Katsuno T; Pradhan TK; Ryan RR; Mantey SA; Hou W; Donohue PJ; Akeson MA; Spindel ER; Battey JF; Coy DH; Jensen RT
Biochemistry; 1999 Jun; 38(22):7307-20. PubMed ID: 10353842
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of cloned human bombesin receptors.
Benya RV; Kusui T; Pradhan TK; Battey JF; Jensen RT
Mol Pharmacol; 1995 Jan; 47(1):10-20. PubMed ID: 7838118
[TBL] [Abstract][Full Text] [Related]
10. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14).
Reubi JC; Wenger S; Schmuckli-Maurer J; Schaer JC; Gugger M
Clin Cancer Res; 2002 Apr; 8(4):1139-46. PubMed ID: 11948125
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology and intracellular signaling mechanisms of the native human orphan receptor BRS-3 in lung cancer cells.
Ryan RR; Weber HC; Mantey SA; Hou W; Hilburger ME; Pradhan TK; Coy DH; Jensen RT
J Pharmacol Exp Ther; 1998 Oct; 287(1):366-80. PubMed ID: 9765358
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.
Höhne A; Mu L; Honer M; Schubiger PA; Ametamey SM; Graham K; Stellfeld T; Borkowski S; Berndorff D; Klar U; Voigtmann U; Cyr JE; Friebe M; Dinkelborg L; Srinivasan A
Bioconjug Chem; 2008 Sep; 19(9):1871-9. PubMed ID: 18754574
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent.
Karra SR; Schibli R; Gali H; Katti KV; Hoffman TJ; Higginbotham C; Sieckman GL; Volkert WA
Bioconjug Chem; 1999; 10(2):254-60. PubMed ID: 10077475
[TBL] [Abstract][Full Text] [Related]
14. Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands.
Mantey SA; Gonzalez N; Schumann M; Pradhan TK; Shen L; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2006 Nov; 319(2):980-9. PubMed ID: 16943256
[TBL] [Abstract][Full Text] [Related]
15. Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirect pathways.
Furutani N; Hondo M; Tsujino N; Sakurai T
J Mol Neurosci; 2010 Sep; 42(1):106-11. PubMed ID: 20467915
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors.
Moreno P; Mantey SA; Nuche-Berenguer B; Reitman ML; González N; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2013 Oct; 347(1):100-16. PubMed ID: 23892571
[TBL] [Abstract][Full Text] [Related]
17. Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3.
Mantey SA; Coy DH; Pradhan TK; Igarashi H; Rizo IM; Shen L; Hou W; Hocart SJ; Jensen RT
J Biol Chem; 2001 Mar; 276(12):9219-29. PubMed ID: 11112777
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.
Gonzalez N; Hocart SJ; Portal-Nuñez S; Mantey SA; Nakagawa T; Zudaire E; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2008 Feb; 324(2):463-74. PubMed ID: 18006692
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptides, antagonists and cell proliferation: bombesin as an example.
Dietrich JB
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):731-46. PubMed ID: 7812181
[TBL] [Abstract][Full Text] [Related]
20. Development of highly potent and selective dynorphin A analogues as new medicines.
Lung FD; Chen CH; Liu JH
J Pept Res; 2005 Nov; 66(5):263-76. PubMed ID: 16218994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
